ADAM9 functions as a transcriptional regulator to drive angiogenesis in esophageal squamous cell carcinoma
Yu-Sen Lin, Ting-Ting Kuo, Chia-Chien Lo, Wei‐Chung Cheng, Wei-Chao Chang, Guan-Chin Tseng, Shih-Ting Bai, Yukai Huang, Chih-Ying Hsieh, Han‐Shui Hsu, Yi-Fan Jiang, Chen-Yuan Lin, Liang‐Chuan Lai, Li X, Yuh‐Pyng Sher
Abstract
Hypoxia and angiogenesis play key roles in the pathogenesis of esophageal squamous cell carcinoma (ESCC), but regulators linking these two pathways to drive tumor progression remain elusive. Here we provide evidence of ADAM9's novel function in ESCC progression. Increasing expression of ADAM9 was correlated with poor clinical outcomes in ESCC patients. Suppression of ADAM9 function diminished ESCC cell migration and in vivo metastasis in ESCC xenograft mouse models. Using cellular fractionation and imaging, we found a fraction of ADAM9 was present in the nucleus and was uniquely associated with gene loci known to be linked to the angiogenesis pathway demonstrated by genome-wide ChIP-seq. Mechanistically, nuclear ADAM9, triggered by hypoxia-induced translocation, functions as a transcriptional repressor by binding to promoters of genes involved in the negative regulation of angiogenesis, and thereby promotes tumor angiogenesis in plasminogen/plasmin pathway. Moreover, ADAM9 suppresses plasminogen activator inhibitor-1 gene transcription by interacting with its transcription factors at the promoter. Our findings uncover a novel regulatory mechanism of ADAM9 as a transcriptional regulator in angiogenesis and highlight ADAM9 as a promising therapeutic target for ESCC treatment.